Metabolic-associated steatohepatitis (MASH) is an advanced and progressive liver disease that potentially causes cirrhosis ...

For decades, MASH has reigned as one of the smartest, most heartfelt, and downright funniest wartime comedy series of all ...

Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...

Prime Day has no shortage of great deals on both LEGO sets and popular board games. But what if I told you you can get both ...

"We’re helping hip-hop and classical music grow and expand beyond their boundaries," Cypress Hill's "Sen Dog" says.

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

In parallel, e-therapeutics has successfully completed GMP manufacturing of the clinical batch of ETX-312, supporting the Company’s operational readiness to progress to first-in-human dosing.

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

First responders and future medical professionals kicked into high gear Wednesday when they found themselves faced with a ...